T: +44 (0)114 222 2261
A phase 3 clinical genetic therapy trial led by Prof Dame Pamela Shaw and Prof Chris McDermott in the UK to treat the SOD1-linked subtype of motor neurone disease (MND) could be a turning point for patient care, after the results showed significant physical benefits for patients after 12 months.
Today (11th April) is World Parkinson’s Day. Parkinson’s is the fastest growing neurological condition in the world, 1 in 37 people alive today in the UK will be diagnosed with Parkinson’s in their lifetime. Annual costs resulting from Parkinson’s exceed $ 50 Billion dollars in the US alone.
Scientists at the University of Sheffield believe the pioneering study represents a significant step towards unravelling the link between high levels of physical activity and the development of the neurodegenerative condition which affects approximately 5,000 people in the UK.
A pioneering gene therapy innovation centre at the University of Sheffield is set to advance scientific discoveries into promising treatment options for millions of patients with life-threatening diseases.